Early Promise for New Drug in Aortic Stenosis Treatment
Early Promise for New Drug in Aortic Stenosis Treatment
Source:
Highlighted by AHA : March 24, 2025
Original publication: Circulation
1. Objective:
• Investigate the potential of a new drug, ataciguat, to treat aortic stenosis (AS) without TAVR or SAVR.
2. Mechanism:
• Ataciguat reactivates oxidized soluble guanylate cyclase, reducing signals that drive fibrocalcific aortic valve stenosis (FCAVS).
3. Study Summary:
• Phase I trial: Ataciguat was well tolerated in patients with FCAVS.
• Phase II trial: Six months of treatment reduced aortic valve calcification progression by ~70% compared to placebo.
4. Clinical Significance:
• The drug showed potential to delay or avoid valve replacement procedures in moderate AS cases.
• Also showed signs of slowing valvular and ventricular dysfunction.
5. Next Steps:
• A phase III trial is in progress to evaluate long-term efficacy and safety.
• Further studies are needed to assess broader cardiovascular outcomes.
